Mastroroberto Pasquale, Onorati Francesco, Zofrea Saverio, Renzulli Attilio, Indolfi Ciro
Department of Experimental and Clinical Medicine, Cardiovascular Surgery Unit University Magna Graecia, viale Europa, 88100 Catanzaro, Italy.
J Cardiothorac Surg. 2010 Apr 9;5:23. doi: 10.1186/1749-8090-5-23.
The aim of the study was to analyze surgical and endovascular results in the treatment of acute type B aortic dissection (B AAD).
Retrospective and observational analysis with patient inclusion between January 2001-December 2008 and follow-up ranged from 2 to 96 months (median = 47.2) was performed. Out of 51 consecutive patients with B AAD, 11 (21.6%) had to undergo open surgery (OS) and 13 (25.5%) endovascular treatment (TEVAR).
There was a significantly difference in early mortality in the TEVAR group (0/13,0%) vs OS group (4/11,36.4%, P < 0.05) and in the incidence of paraplegia/paraparesis (OS 2,28.6% vs TEVAR 1,7.7%, P < 0.05), renal failure (OS 3, 42.8% vs TEVAR 1, 7.7%, P < 0.05), respiratory failure (OS 2,28.6% vs TEVAR 1,7.7%, P < 0.05) and cerebrovascular accident (OS 1,14.3% vs TEVAR 0,0%, P < 0.05). The late mortality at a follow-up was 30.8% (4/13) in the TEVAR group and 42.8% (3/7) in the OS group, respectively (P = not significant). The cumulative survival rate after 1, 3 and 8 years was 93%, 84%, and 69% in the TEVAR group and 86%, 71% and 57% in the OS group, respectively. Endoleaks were diagnosed in 2/13 endovascular patients (15.4%).
TEVAR group had a significantly reduction in early mortality and postoperative complications. No significant differences were found in terms of cumulative survival at follow-up. On this basis TEVAR could be considered an option in the treatment of these complex cases with all proper reservation especially related to the small sample sizes examined.
本研究旨在分析急性B型主动脉夹层(B型主动脉夹层)的手术和血管内治疗结果。
进行回顾性观察分析,纳入2001年1月至2008年12月期间的患者,随访时间为2至96个月(中位数 = 47.2个月)。在连续51例B型主动脉夹层患者中,11例(21.6%)接受了开放手术(OS),13例(25.5%)接受了血管内治疗(TEVAR)。
TEVAR组与OS组相比,早期死亡率(TEVAR组0/13,0% 对比OS组4/11,36.4%,P < 0.05)、截瘫/轻瘫发生率(OS组2例,28.6% 对比TEVAR组1例,7.7%,P < 0.05)、肾衰竭(OS组3例,42.8% 对比TEVAR组1例,7.7%,P < 0.05)、呼吸衰竭(OS组2例,28.6% 对比TEVAR组1例,7.7%,P < 0.05)及脑血管意外(OS组1例,14.3% 对比TEVAR组0例,0%,P < 0.05)均存在显著差异。随访时TEVAR组的晚期死亡率为30.8%(4/13),OS组为42.8%(3/7)(P = 无显著性差异)。TEVAR组1年、3年和8年后的累积生存率分别为93%、84%和69%,OS组分别为86%、71%和57%。13例接受血管内治疗的患者中有2例(15.4%)诊断出内漏。
TEVAR组早期死亡率和术后并发症显著降低。随访时累积生存率方面未发现显著差异。在此基础上,TEVAR可被视为治疗这些复杂病例的一种选择,但需保留所有适当的条件,特别是与所检查的小样本量相关的条件。